Acrivon Therapeutics, Inc. Common Stock (ACRV) EBITDA Yield: History & Chart

Acrivon Therapeutics, Inc. Common Stock(ACRV)

Biotechnology · Watertown, MA

$2.04+0.06 (+2.78%)

Delayed quote: Oct 6, 2026, 9:43 AM EDT

About Acrivon Therapeutics, Inc. Common Stock

Acrivon Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company primarily focused on creating oncology treatments. The firm employs a unique strategy to identify patients whose tumors are predicted to be sensitive to specific medications, utilizing its proprietary proteomics-based platform for patient identification. This advanced system, named Acrivon Predictive Precision Proteomics (AP3), serves as a precision medicine tool. It is instrumental in developing drug-specific OncoSignature companion diagnostics, which are designed to pinpoint individuals most likely to benefit from the company's therapeutic candidates. Acrivon's flagship clinical asset is ACR-368, a selective small molecule inhibitor that targets both CHK1 and CHK2. This candidate is currently undergoing a potentially pivotal Phase 2 trial for a range of advanced tumor types, notably including platinum-resistant ovarian, endometrial, and bladder cancers. Beyond its lead program, the company is also cultivating several early-stage pipeline programs. These initiatives concentrate on crucial regulatory points within the DNA damage response and cell cycle regulation pathways, specifically identifying targets such as the protein kinases WEE1 and PKMYT1. Established in 2018, Acrivon Therapeutics, Inc. maintains its headquarters in Watertown, Massachusetts.

Watertown, MA

75 employees

www.acrivon.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Peter Blume-Jensen

View full financials

NAME	MARKET CAP	EBITDA YIELD	TTM	3Y	5Y
Acrivon Therapeutics, Inc. Common Stock (ACRV)	$87.10M	N/A	N/A	N/A	N/A
Citius Oncology, Inc. (CTOR)vs ›	$85.53M	N/A	N/A	N/A	N/A
Humacyte, Inc. (HUMA)vs ›	$84.52M	N/A	N/A	N/A	N/A
Cognition Therapeutics, Inc. (CGTX)vs ›	$84.44M	N/A	N/A	N/A	N/A
CareCloud, Inc. (CCLD)vs ›	$87.11M	21.53%	23.06%	41.09%	38.38%
Atara Biotherapeutics, Inc. (ATRA)vs ›	$83.97M	N/A	17.90%	17.90%	17.90%
Cardiff Oncology, Inc. (CRDF)vs ›	$88.63M	N/A	N/A	N/A	N/A
Conexeu Sciences Inc. (CNXU)vs ›	$88.84M	N/A	N/A	N/A	N/A
ImmuCell Corporation (ICCC)vs ›	$89.11M	6.74%	6.57%	5.72%	4.64%
LENSAR Inc (LNSR)vs ›	$81.80M	N/A	N/A	N/A	N/A

NAME

MARKET CAP

EBITDA YIELD

TTM

Acrivon Therapeutics, Inc. Common Stock (ACRV)

$87.10M

N/A

Citius Oncology, Inc. (CTOR)vs ›

$85.53M

N/A

Humacyte, Inc. (HUMA)vs ›

$84.52M

N/A

Cognition Therapeutics, Inc. (CGTX)vs ›

$84.44M

N/A

CareCloud, Inc. (CCLD)vs ›

$87.11M

21.53%

23.06%

41.09%

38.38%

Atara Biotherapeutics, Inc. (ATRA)vs ›

$83.97M

N/A

17.90%

Cardiff Oncology, Inc. (CRDF)vs ›

$88.63M

N/A

Conexeu Sciences Inc. (CNXU)vs ›

$88.84M

N/A

ImmuCell Corporation (ICCC)vs ›

$89.11M

6.74%

6.57%

5.72%

4.64%

LENSAR Inc (LNSR)vs ›

$81.80M

N/A

EBITDA Yield Formula & Definition

EBITDA Yield = TTM EBITDA / Enterprise Value

EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.

EBITDA Yield: N/A

ACRV EBITDA Yield Metrics

ACRV Competitors' EBITDA Yield

EBITDA Yield Formula & Definition

Related Metrics